Spero Therapeutics, Inc. — Director's Dealing 2018

Jun 6, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2018-06-05

Reporting Person: Deshpande Milind (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-05	Stock Option (right to buy)	$11.54	A	6073	Acquired	2028-06-05	Common Stock (6073)	Direct

Footnotes

F1: The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date.